TY - JOUR
T1 - Real-World Outcomes of Older Patients with Primary Central Nervous System Lymphoma (PCNSL)
T2 - Methotrexate Dose Intensity and Combination with Cytarabine Correlate with Response and Survival
AU - Martinez-Calle, Nicolas
AU - Poynton, Edward
AU - Alchawaf, Alia
AU - Kassam, Shireen
AU - Horan, Matthew
AU - Rafferty, Mark
AU - Kelsey, Phillipa
AU - Scott, Gemma
AU - Bruce, Stephanie
AU - Buckley, Hannah
AU - Jones, Sophie
AU - Lim, Yeong Jer
AU - Loretta, Ngu
AU - Lewis, David
AU - Ajithkumar, Thankamma
AU - Culligan, Dominic J.
AU - Rowntree, Clare
AU - Wright, Josh
AU - McKay, Pamela
AU - Fourali, Samih
AU - Eyre, Toby A.
AU - Smith, Jeffrey
AU - Osborne, Wendy
AU - Yallop, Deborah
AU - Linton, Kim
AU - Fox, Christopher P.
AU - Cwynarski, Kate
PY - 2018/11/29
Y1 - 2018/11/29
N2 - Primary central nervous system lymphoma (PCNSL) in patients (pts) over 65 years old have poorer outcome compared to younger cohorts, as comorbidities, baseline performance status and susceptibility to iatrogenic toxicity impede adequate drug delivery (Kasenda et al, Ann Oncol, 2015). Balancing toxicity against treatment benefits remains a challenge in this age group. Recent trials have attempted to rationalize treatment aiming for reduced toxicity whilst maintaining CNS penetration. Efficacy of additional agents, such as oral alkylators (Fritsch et al, Leukemia 2017) has also been demonstrated. Most clinical trial cohorts underrepresent elderly pts and thus analysis of real-world outcomes and therapeutic practice is warranted.
AB - Primary central nervous system lymphoma (PCNSL) in patients (pts) over 65 years old have poorer outcome compared to younger cohorts, as comorbidities, baseline performance status and susceptibility to iatrogenic toxicity impede adequate drug delivery (Kasenda et al, Ann Oncol, 2015). Balancing toxicity against treatment benefits remains a challenge in this age group. Recent trials have attempted to rationalize treatment aiming for reduced toxicity whilst maintaining CNS penetration. Efficacy of additional agents, such as oral alkylators (Fritsch et al, Leukemia 2017) has also been demonstrated. Most clinical trial cohorts underrepresent elderly pts and thus analysis of real-world outcomes and therapeutic practice is warranted.
KW - Autologous stem cell transplant
KW - DLBCL
KW - High Dose Methotrexate
KW - Lymphoma
KW - Primary Central Nervous System Lymphoma
KW - Primary CNS Lymphoma
U2 - 10.1182/blood-2018-99-111901
DO - 10.1182/blood-2018-99-111901
M3 - Meeting Abstract
SN - 0006-4971
VL - 132
SP - 572
EP - 575
JO - Blood
JF - Blood
IS - Supplement 1
ER -
